Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial

Akın, İbrahim; Brugier, Delphine; Collet, Jean‐Philippe; Waha‐Thiele, Suzanne de; Greenwood, John P; Hauguel-Moreau, Marie; Huber, Kurt; Kernéis, Mathieu; Noč, Marko; Oldroyd, Keith G.; Rouanet, Stéphanie; Savonitto, Stefano; Šerpytis, Pranas; Silvain, Johanne; Stępińska, Janina; Vicaut, Éric; Vrints, Christiaan J.; Windecker, Stephan; Thiele, Holger; Desch, Steffen; Zeymer, Uwe; Montalescot, Gilles; Piek, Jan J.; Torremante, Patrizia; Meyer‐Saraei, Roza; Tebbe, Ulrich; Wöhrle, Jochen; Pachinger, Otmar; Neumer, Alexander; Busch, Clemens; Pfeiffer, Nathalie; Schneider, Steffen; Ouarrak, Taoufik; Reimer, Thomas; Lober, Christiane; Clemmensen, Peter; Folláth, Ferenc; Wegscheider, Karl; Barthélémy, Olivier; Zeitouni, Michel; Overtchouk, Pavel; Guedeney, Paul; Hage, Georges; Hauguel-Moreau,

doi:10.1016/j.chest.2020.10.089

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, among patients who developed CS, those without ST-segment elevation had more frequently several adverse baseline characteristics than those with ST-segment elevation, such as significantly older age, and a greater frequency of prior infarction, multivessel disease and congestive heart failure [ 29 , 30 , 31 ].…”

Section: Cardiogenic Shock Complicating Acute Coronary Syndromesmentioning

confidence: 99%

When to Achieve Complete Revascularization in Infarct-Related Cardiogenic Shock

Masiero

Cardaioli

Rodinò

et al. 2022

JCM

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is a life-threatening condition frequently encountered in patients with multivessel coronary artery disease (CAD). Despite prompt revascularization, in particular, percutaneous coronary intervention (PCI), and therapeutic and technological advances, the mortality rate for patients with CS related to AMI remains unacceptably high. Differently form a hemodynamically stable setting, a culprit lesion-only (CLO) revascularization strategy is currently suggested for AMI–CS patients, based on the results of recent randomized evidence burdened by several limitations and conflicting results from non-randomized studies. Furthermore, mechanical circulatory support (MCS) devices have emerged as a key therapeutic option in CS, especially in the case of their early implantation without delaying revascularization and before irreversible organ damage has occurred. We provide an in-depth review of the current evidence on optimal revascularization strategies of multivessel CAD in infarct-related CS, assessing the role of different types of MCS devices and highlighting the importance of shock teams and medical care system networks to effectively impact on clinical outcomes.

show abstract

Section: Cardiogenic Shock Complicating Acute Coronary Syndromesmentioning

confidence: 99%

When to Achieve Complete Revascularization in Infarct-Related Cardiogenic Shock

Masiero

Cardaioli

Rodinò

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Percutaneous coronary intervention (PCI) is the preferred strategy, and it could rapidly re-canalize the infarct arteries, significantly reduce infarct area, and improve clinical outcome and long-term prognosis. [ 3 , 4 ]…”

Section: Introductionmentioning

confidence: 99%

Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients

Huang²,

Wang³

et al. 2021

Medicine

View full text Add to dashboard Cite

Introduction: An acute ST-elevation myocardial infarction (STEMI) is a very serious type of heart attack and a profoundly life-threatening medical emergency, and percutaneous coronary intervention (PCI) is the preferred strategy. However, in patients undergoing primary PCI, 30% to 40% may suffer the no-reflow phenomenon (NRP), and it could expand the myocardial infarction area and accompanied with high rehospitalization rate and fatality rate. In this study, we try to conduct a double blinded, randomized, placebo-controlled trial to observe whether the prophylactically intracoronary administration of Nicorandil could reduce the occurrence of NRP in STEMI patients undergoing PCI. Methods: Simple randomization in a 1:1 ratio will be made in blocks of variable size according to a random numbers generated by Excel 2010 to divide the patients to treatment group (Nicorandil) and control group (Saline). The outcomes are the occurrence of NRP, levels of interleukin-6 and HS-CRP, cTnT, and CK-MB before, and every 4 hours following PCI, and major adverse cardiovascular events at day 30. SPSS 23.0 (IBM, Chicago, IL) will be used, and P -value < .05 will be considered statistically significant. Conclusions: The findings will determine the efficacy of prophylactically intracoronary administration of Nicorandil to reduce the occurrence of NRP during PCI in acute STEMI patients. Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/QPF3V

show abstract

“…In this issue of CHEST, Zeituni et al 8 performed a post hoc analysis of the CULPRIT SHOCK data according to the ECG at presentation. ST-segment elevation was present in 59.5% of patients, and 14.7% presented with LBBB.…”

mentioning

confidence: 99%